Mersana Therapeutics, Inc.

Bayer Healthcare LLC

Bayer Aktiengesellschaft

Bayer Pharmaceuticals Corporation

Bayer Corporation

Asana Biosciences, LLC

Axikin Pharmaceuticals, Inc.

Bayer Healthcare Aktiengesellschaft

Mersana Therpeutics, Inc.

Timothy B Lowinger

Aleksandr V Yurkovetskiy

Mao Yin

Cheri A Stevenson

Joshua D Thomas

Natalya D Bodyak

Patrick R Conlon

Charles E Hammond

Dmitry R Gumerov

Roger Astbury Smith

Jacques P Dumas

William Johnston Scott

Jill E Wood

Uday R Khire

Robert Sibley

Toshiki Murata

Peter U Park

Bernd Riedl

Eugene W Kelleher

Takuya Shintani

Takashi Yoshino

Yuji Koriyama

Kinji Fuchikami

Bingfan Du

Hiroki Sato

Dorin Toader

Sachiko Sakakibara

Marc I Damelin

Venu Reddy Gurijala

Shuyi Tang

Bianka Prinz

Eric Krauland

Kevin Bacon

Tsutomu Masuda

Holia Hatoum-Mokdad

Karl Ziegelbauer

Hiroshi Komura

Masaomi Umeda

Keiko Fukushima

Hiroshi Kadono

Joel Renick

Noriko Nunami

Mary-Katherine Monahan

Reina Natero

Michael J DeVit

Megumi Yamauchi

Nitin Krishnaji Damle

Klaus Urbahns

David R Brittelli

David Gunn

Michael C VanZandt

Toshiya Moriwaki

Liping Yang

Aniko Redman

Yingfu Li

Jeffrey Johnson

Jeremy R Duvall

Keith W Bentley

Norihiro Kawamura

Hiroko Yoshino

Bernard Riedl

Takashi Yoshiro

Mitsuiyuki Shimada

Hanno Roder

Naniye Cetinbas

Raghida A Bukhalid

Ling Xu

Akihiko Watanabe

Tetsuo Kikuchi

Mariya Kozytska

Russell Colyn Petter

John Henry Van Duzer

Rolf Grosser

Mitsuyuki Shimada

Ming Wang

Laura L Poling

Catherine R Brennan

Scott Miller

Martin Osterhout

Brian D Jones

Donald A Bergstrom

Gui Liu

Tiffany Turner

Laura C Akullian

John J Kane

Marell Rodriguez

Satyanarayan Reddy Bollu

Jacques Leblanc

Dennis McGillicuddy

Chen-Ni Chin

Carolina B Cabral

Ahmed Hilmy

Dimitry R Gumerov

Robert N Sibley

Michael J Devit

Eric M Krauland

Yoshino Hiroko

The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Antibody drug conjugates comprising sting agonists

The present disclosure relates generally to antibody-drug conjugates comprising monoclonal antibodies that specifically bind the human B7-H4 in soluble form, or membrane bound (i.e., when expressed on a cell surface) and to methods of using these conjugates as therapeutics and/or diagnostics.

B7H4-targeted antibody-drug conjugates and methods of use thereof

The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.

Peptide-containing linkers for antibody-drug conjugates

Site specific antibody-drug conjugates with peptide-containing linkers

The present disclosure relates generally to antibody-drug conjugates comprising pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) drug moieties. The present disclosure also relates to methods of using these conjugates, e.g., as therapeutics and/or diagnostics.

Pyrrolobenzodiazepine antibody conjugates

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

Monoclonal antibodies against HER2 epitope and methods of use thereof

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

Protein-polymer-drug conjugates

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

NaPi2b-targeted antibody-drug conjugates and methods of use thereof

The disclosure provides methods of synthesis of polymeric scaffolds, e.g., those useful for conjugating with a protein based recognition-molecule (PBRM) to form PBRM-polymer-drug conjugates, and PBRM-polymer-drug conjugates thereof. The methods according to the disclosure allow for large-scale preparation of polymeric scaffolds having a high purity. In some embodiments, the methods according to the disclosure also allow for the preparation of scaffolds and conjugates thereof in better yield than previously used methods for preparing same. Also disclosed are methods of purifying polymeric scaffolds.

Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates

The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.

Pyrrolobenzodiazepines and conjugates thereof

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L-D, the protein based recognition-molecule being connected to the polymeric carrier by L. Each occurrence of D is independently a therapeutic agent having a molecular weight&#x2264;5 kDa. Land Lare linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L-D, the protein based recognition-molecule being connected to the polymeric carrier by L. Each occurrence of D is independently an Auristatin compound. Land Lare linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Growing community of inventors

Carlisle, MA, United States of America

Timothy B Lowinger